Comparison of allogeneic stem cell transplantation,high-dose cytarabine,and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia |
| |
| Authors: | Tsimberidou Apostolia-Maria,Stavroyianni Niki,Viniou Nora,Papaioannou Maria,Tiniakou Maria,Marinakis Theodoros,Skandali Anastasia,Sakellari Ioanna,Yataganas Xenophon Hellenic Cooperative Group |
| |
| Affiliation: | First Department of Internal Medicine, National University of Athens, Medical School, Laiko General Hospital, Athens, Greece. atsimber@mail.mdanderson.org |
| |
| Abstract: | ![]()
BACKGROUND: Postremission therapy is critical in maintaining complete remission (CR) in patients with de novo acute myelogenous leukemia (AML). The aim of this trial was to compare allogeneic stem cell transplantation (SCT), high-dose cytarabine (ara-C; HiDAC), and autologous SCT as postremission therapy in patients with de novo AML. METHODS: One hundred twenty patients age
|
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
